Search Within

Ronald A Ghossein

  1. "Molecular Pharmacology and Chemistry Program Faculty"
Formats
  1. Journal Article (28)
  2. Meeting Abstract (4)
  3. Editorial (1)
Groups
  1. Department of Pathology and Laboratory Medicine (33)
  2. Molecular Pharmacology and Chemistry Program Faculty (33)
  3. Sloan Kettering Institute Faculty (33)
  4. Department of Medicine (20)
  5. GSK Faculty (19)
  6. Division of Subspecialty Medicine (18)

More Groups

People
  1. Murray Brennan (14)
  2. Steven Larson (14)
  3. James Fagin (13)
  4. Robert Tuttle (12)
  5. Ashok Shaha (10)
  6. Ravinder Grewal (9)

More People

Years
  1. 2024 (2)
  2. 2023 (2)
  3. 2022 (2)
  4. 2021 (1)
  5. 2019 (1)
  6. 2015 (1)

More Years

Publications
  1. Journal of Clinical Endocrinology and Metabolism (4)
  2. Annals of Surgical Oncology (3)
  3. European Journal of Nuclear Medicine and Molecular Imaging (3)
  4. Journal of Clinical Oncology (3)
  5. Surgery (3)
  6. American Journal of Pathology (1)

More Publications

Publishers
  1. Springer (7)
  2. Elsevier Inc. (4)
  3. Oxford University Press (4)
  4. American Association for Cancer Research (3)
  5. American Society of Clinical Oncology (3)
  6. Elsevier Science, Inc. (2)

More Publishers

Results (33)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • [(18)F]TFB PET/CT misses intense [(124)I]iodine-avid metastases after redifferentiation therapy in metastatic thyroid cancer
    Journal Article

    Backhaus, P.; Pentlow, K. S.; Ho, A. L.; Mauguen, A.; Fagin, J. A.; Pillarsetty, N. V. K.; Lyashchenko, S. K.; Burnazi, E.; Ghossein, R. A.; Chhabra, S.; more...
    EJNMMI Research (2024)

    Fulltext@MSK | Save
  • Toward individualized dosimetry for radiopharmaceutical therapy in day-to-day clinical practice of nuclear oncology: Overcoming heterogeneity of radiation-absorbed dose to tumor and critical organs
    Editorial

    Bodei, L.; Tuttle, R. M.; Grewal, R. K.; Mauguen, A.; Augensen, F.; Abusamra, M.; Mahajan, S.; Jayaprakasam, V. S.; Osborne, J. R.; Haque, S.; more...
    European Journal of Nuclear Medicine and Molecular Imaging (2024)

    Fulltext@MSK | Save
  • Prospective comparison of F-18-TFB and I-124 PET/CT in metastatic thyroid cancer
    Meeting Abstract

    Backhaus, P.; Pentlow, K.; Ho, A. L.; Mauguen, A.; Fagin, J. A.; Pillarsetty, N. V. K.; Lyashchenko, S. K.; Burnazi, E.; Ghossein, R. A.; Chhabra, S.; more...
    European Journal of Nuclear Medicine and Molecular Imaging (2023)

    Fulltext@MSK | Save
  • The use of single-timepoint images to link administered radioiodine activity (MBq) to a prescribed lesion radiation-absorbed dose (cGy): A regression-based prediction interval tool for the management of well-differentiated thyroid cancer patients
    Journal Article

    Mauguen, A.; Grewal, R. K.; Augensen, F.; Abusamra, M.; Mahajan, S.; Jayaprakasam, V. S.; Osborne, J.; Haque, S.; Wong, B. Z. Y.; Ghossein, R. A.; more...
    European Journal of Nuclear Medicine and Molecular Imaging (2023)

    Fulltext@MSK | Save
  • Phase 2 of trametinib plus radioiodine in RAS-mutant and wild-type, radioiodine-refractory thyroid cancer (ETCTN9446)
    Meeting Abstract

    Burman, B.; Tuttle, R. M.; Grewal, R. K.; Sherman, E. J.; Baxi, S. S.; Boucai, L.; Sabra, M.; Fish, S.; Pentlow, K. S.; Haque, S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Enhancing radioiodine incorporation in BRAF-mutant, radioiodine-refractory thyroid cancers with vemurafenib and the anti-ERBB3 monoclonal antibody CDX-3379: Results of a pilot clinical trial
    Journal Article

    Tchekmedyian, V.; Dunn, L.; Sherman, E.; Baxi, S. S.; Grewal, R. K.; Larson, S. M.; Pentlow, K. S.; Haque, S.; Tuttle, R. M.; Sabra, M. M.; more...
    Thyroid (2022)

    Fulltext@MSK | Save
  • Prophylactic lateral neck dissection for medullary thyroid carcinoma is not associated with improved survival
    Journal Article

    Spanheimer, P. M.; Ganly, I.; Chou, J. F.; Capanu, M.; Nigam, A.; Ghossein, R. A.; Tuttle, R. M.; Wong, R. J.; Shaha, A. R.; Brennan, M. F.; more...
    Annals of Surgical Oncology (2021)

    Fulltext@MSK | Save
  • Vemurafenib redifferentiation of BRAF mutant, RAI-refractory thyroid cancers
    Journal Article

    Dunn, L. A.; Sherman, E. J.; Baxi, S. S.; Tchekmedyian, V.; Grewal, R. K.; Larson, S. M.; Pentlow, K. S.; Haque, S.; Tuttle, R. M.; Sabra, M. M.; more...
    Journal of Clinical Endocrinology and Metabolism (2019)

    Fulltext@MSK | Save
  • AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas
    Journal Article

    Elkabets, M.; Pazarentzos, E.; Juric, D.; Sheng, Q.; Pelossof, R. A.; Brook, S.; Benzaken, A. O.; Rodon, J.; Morse, N.; Yan, J. J.; more...
    Cancer Cell (2015)

    Fulltext@MSK | Save
  • Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF mutant thyroid carcinomas
    Meeting Abstract

    Montero-Conde, C.; Ruiz-Llorente, S.; Domínguez, J. M.; Knauf, J. A.; Viale, A.; Sherman, E. J.; Ryder, M.; Ghossein, R. A.; Rosen, N.; Fagin, J. A.
    Cancer Research (2013)

    Fulltext@MSK | Save